MX2017001218A - [1,2,4]triazolo[4,3-b]piridazinas para uso en el tratamiento de enfermedades proliferativas. - Google Patents

[1,2,4]triazolo[4,3-b]piridazinas para uso en el tratamiento de enfermedades proliferativas.

Info

Publication number
MX2017001218A
MX2017001218A MX2017001218A MX2017001218A MX2017001218A MX 2017001218 A MX2017001218 A MX 2017001218A MX 2017001218 A MX2017001218 A MX 2017001218A MX 2017001218 A MX2017001218 A MX 2017001218A MX 2017001218 A MX2017001218 A MX 2017001218A
Authority
MX
Mexico
Prior art keywords
pyridazines
triazolo
treatment
proliferative diseases
formula
Prior art date
Application number
MX2017001218A
Other languages
English (en)
Inventor
Hugh Bradbury Robert
Arthur Rabow Alfred
James Waring Michael
Christopher Glossop Steven
Mahmood Arshed
Francis Mccabe James
Ann Cotter Zoe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2017001218A publication Critical patent/MX2017001218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH DRILLING; MINING
    • E21B—EARTH DRILLING, e.g. DEEP DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E—FIXED CONSTRUCTIONS
    • E21—EARTH DRILLING; MINING
    • E21B—EARTH DRILLING, e.g. DEEP DRILLING; OBTAINING OIL, GAS, WATER, SOLUBLE OR MELTABLE MATERIALS OR A SLURRY OF MINERALS FROM WELLS
    • E21B7/00—Special methods or apparatus for drilling
    • E21B7/04—Directional drilling
    • E21B7/06—Deflecting the direction of boreholes
    • E21B7/062—Deflecting the direction of boreholes the tool shaft rotating inside a non-rotating guide travelling with the shaft
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La invención se refiere a compuestos de la Fórmula (I) (ver Fórmula) o sus sales farmacéuticamente aceptables, donde R1, R2 y n tienen cualquiera de los significados definidos anteriormente en la presente en la descripción; procesos para su preparación, composiciones farmacéuticas que los contienen y su uso como agentes antiproliferativos y/o aniquiladores de células.
MX2017001218A 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]piridazinas para uso en el tratamiento de enfermedades proliferativas. MX2017001218A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029676P 2014-07-28 2014-07-28
PCT/GB2015/052143 WO2016016618A1 (en) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
MX2017001218A true MX2017001218A (es) 2017-05-01

Family

ID=53761420

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001218A MX2017001218A (es) 2014-07-28 2015-07-24 [1,2,4]triazolo[4,3-b]piridazinas para uso en el tratamiento de enfermedades proliferativas.

Country Status (36)

Country Link
US (5) US9944650B2 (es)
EP (1) EP3174881B1 (es)
JP (1) JP6592503B2 (es)
KR (1) KR20170033427A (es)
CN (1) CN106536524B (es)
AP (1) AP2017009700A0 (es)
AU (1) AU2015295120B2 (es)
BR (1) BR112017001160A2 (es)
CA (2) CA3185741A1 (es)
CL (1) CL2017000223A1 (es)
CO (1) CO2017001918A2 (es)
CY (1) CY1120602T1 (es)
DK (1) DK3174881T3 (es)
DO (1) DOP2017000018A (es)
EA (1) EA032654B9 (es)
ES (1) ES2670444T3 (es)
GT (1) GT201700016A (es)
HR (1) HRP20180788T1 (es)
HU (1) HUE037571T2 (es)
IL (1) IL250104B (es)
LT (1) LT3174881T (es)
MX (1) MX2017001218A (es)
MY (1) MY187251A (es)
NI (1) NI201700006A (es)
NO (2) NO2719005T3 (es)
PE (1) PE20170527A1 (es)
PH (1) PH12017500159B1 (es)
PL (1) PL3174881T3 (es)
PT (1) PT3174881T (es)
RS (1) RS57242B1 (es)
SG (1) SG11201700419SA (es)
SI (1) SI3174881T1 (es)
SV (1) SV2017005368A (es)
TN (1) TN2017000018A1 (es)
WO (1) WO2016016618A1 (es)
ZA (1) ZA201701207B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2719005T3 (es) * 2014-07-28 2018-01-20
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
TWI816880B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 治療前列腺癌之組合療法
MX2022004555A (es) 2019-10-14 2022-07-21 Astrazeneca Ab Terapia de combinacion para tratar una neoplasia maligna hematologica.
AU2021206140A1 (en) 2020-01-09 2022-08-18 Astrazeneca Ab Combination therapy for treating cancer
CN113143930B (zh) * 2021-04-08 2023-05-30 深圳湾实验室 化合物在制备SARS-Cov-2 E蛋白抑制剂中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007065664A2 (en) 2005-12-08 2007-06-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
GB0525065D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
BRPI0821676A2 (pt) * 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
KR20110113755A (ko) * 2009-02-10 2011-10-18 아스트라제네카 아베 트리아졸로 〔4,3-ｂ〕 피리다진 유도체 및 전립샘암에 대한 이의 용도
AU2010247190A1 (en) * 2009-05-11 2011-11-10 Astrazeneca Ab [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor
CA2779355C (en) 2009-11-05 2018-01-16 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
EP2721031B1 (en) * 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
NO2719005T3 (es) * 2014-07-28 2018-01-20

Also Published As

Publication number Publication date
GT201700016A (es) 2018-12-19
DK3174881T3 (en) 2018-06-06
US20210107905A1 (en) 2021-04-15
PH12017500159A1 (en) 2017-07-10
IL250104B (en) 2018-10-31
AP2017009700A0 (en) 2017-01-31
US20230035133A1 (en) 2023-02-02
MY187251A (en) 2021-09-15
US10407432B2 (en) 2019-09-10
HRP20180788T1 (hr) 2018-06-29
US20180230158A1 (en) 2018-08-16
KR20170033427A (ko) 2017-03-24
NO3174881T3 (es) 2018-08-25
PT3174881T (pt) 2018-05-25
AU2015295120B2 (en) 2018-02-01
US9944650B2 (en) 2018-04-17
AU2015295120A8 (en) 2017-02-09
AU2015295120A1 (en) 2017-02-02
PH12017500159B1 (en) 2017-07-10
IL250104A0 (en) 2017-03-30
TN2017000018A1 (en) 2018-07-04
CA2956421A1 (en) 2016-02-04
CA2956421C (en) 2023-03-14
EP3174881B1 (en) 2018-03-28
CO2017001918A2 (es) 2017-05-10
EP3174881A1 (en) 2017-06-07
EA032654B9 (ru) 2019-07-31
CN106536524B (zh) 2019-11-15
NO2719005T3 (es) 2018-01-20
JP6592503B2 (ja) 2019-10-16
CN106536524A (zh) 2017-03-22
US11407755B2 (en) 2022-08-09
CL2017000223A1 (es) 2017-08-25
NI201700006A (es) 2017-08-25
SG11201700419SA (en) 2017-02-27
SV2017005368A (es) 2017-05-12
JP2017522338A (ja) 2017-08-10
LT3174881T (lt) 2018-06-11
PE20170527A1 (es) 2017-05-24
US20170210747A1 (en) 2017-07-27
CA3185741A1 (en) 2016-02-04
CY1120602T1 (el) 2019-12-11
ZA201701207B (en) 2018-12-19
EA201790179A1 (ru) 2017-07-31
RS57242B1 (sr) 2018-07-31
PL3174881T3 (pl) 2018-08-31
SI3174881T1 (en) 2018-06-29
DOP2017000018A (es) 2017-03-15
EA032654B1 (ru) 2019-06-28
US20200055861A1 (en) 2020-02-20
ES2670444T3 (es) 2018-05-30
HUE037571T2 (hu) 2018-09-28
WO2016016618A1 (en) 2016-02-04
BR112017001160A2 (pt) 2017-11-14
US10766905B2 (en) 2020-09-08

Similar Documents

Publication Publication Date Title
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
PH12015502615B1 (en) Chemical compounds
PH12017500159B1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
PH12015502780A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
TW201613901A (en) New compounds
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
TN2015000313A1 (en) Chemical compounds
TW201613864A (en) Novel compounds
GEP20207172B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12018500650A1 (en) New imidazo [4,5-b] pyridine derivatives, a process for their preparation and pharmaceutical compositions containing them
EP3689875A4 (en) USE OF TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS, AND COMPOSITIONS THEREOF, FOR THE TREATMENT OF PRC2-MEDIATED DISEASES
SI3452465T1 (sl) Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni
MX2017009608A (es) Compuestos anticancerigenos.
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
MX2017008808A (es) Nuevas imidazo[1,2-a]quinoxalinas y derivados de las mismas para el tratamiento contra cancer.

Legal Events

Date Code Title Description
FG Grant or registration